| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | MK-6240 Detection of tau neurofibrillary tangle (NFT) pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease | PDUFA | — | Subscribe to access the data. | Radiopharmaceuticals | Nervous System | |
PDUFA Date example | MK-6240 Detection of tau neurofibrillary tangle (NFT) pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease | PDUFA | — | Subscribe to access the data. | Radiopharmaceuticals | Nervous System | |
PDUFA Date example | MK-6240 Detection of tau neurofibrillary tangle (NFT) pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease | PDUFA | — | Subscribe to access the data. | Radiopharmaceuticals | Nervous System |
Recent Updates
Recently added Catalysts
Lantheus Holdings, Inc.$105.64
-0.35 (-0.33%)
B 76Pipeline Score Diagnostics · Commercial
Market Cap
6.71 B
EPS
4.22
P/E Ratio
24.84 $
Value Trade
107.82 M
SEC Financials
Q1 2026Dilution Risk
Revenue
377.33 M
R&D Expenses
39.38 M
Operating CF
125.13 M
Total Assets
2.35 B
Total Liabilities
1.13 B
Equity
1.21 B
D/E Ratio
12,345
7.16 %
Week
26.27 %
1 Month
40.75 %
3 Month
92.74 %
6 Month
379.74 %
5 Year
1,583.01 %
All Time
Cash Data
Cash Position
498.58 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
942.44 K
52 Week Range
47.25 - 103.89
% held by Insiders
3.52 %
% held by Institutions
115.58 %
Enterprise Value
6.83 B
Total Shares
64.95 M
Short %
9.97 %
Float Shares
63.52 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lantheus Holdings, Inc.
318Total events
5Upcoming
118Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 5
Event history 313
Jun 29, 2026
◆PDUFA DateLNTH-2501Regulatory Filing
PDUFA date extended to June 29, 2026 for LNTH-2501 NDA
somatostatin receptor positive neuroendocrine tumors (NETs)source ↗
Jun 9, 2026
◆Oral PresentationPresentation
Lantheus to present at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 3, 2026
◆Oral PresentationPresentation
Lantheus to present at William Blair 46th Annual Growth Stock Conference
Jun 2, 2026
◆Oral Presentation18F-GP1Presentation
Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis of the lower extremities in symptomatic patients: a phase 2, open-label, non-randomized study
Acute Deep Vein Thrombosissource ↗
Jun 2, 2026
▲Oral PresentationLNTH-2513Presentation
LNTH-2513 PET/CT awarded SNMMI Image of the Year at 2026 Annual Meeting
acute lower-extremity deep vein thrombosissource ↗
Jun 2, 2026
▲Full ResultsLNTH-2513Clinical Data
Investigator-initiated trial results for LNTH-2513 in DVT presented at SNMMI 2026
acute lower-extremity deep vein thrombosissource ↗
Jun 1, 2026
◆Poster PresentationPresentation
Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management for Patients with Low or Ultra-low Prostate-Specific Antigen Levels after Definitive Treatment
Prostate Cancersource ↗
Jun 2026
◆Hatch Waxman LitigationIP / Competition
30-month stay expiration for PNT2003
somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)source ↗
Jun 1, 2026
◆Poster PresentationLNTH2403 Phase 1 dosePresentation
Poster presentation of Phase 1/2 study of LNTH-2403 in osteosarcoma at ASCO 2026
relapsed/refractory osteosarcomasource ↗
May 29, 2026
◆Poster PresentationPresentation
Publication-only presentation on real-world use of piflufolastat F 18 in prostate cancer at ASCO 2026
early-stage prostate cancersource ↗
May 7, 2026
Mar 29, 2026
◆PDUFA DateLNTH-2501Regulatory Filing
FDA sets PDUFA date for LNTH-2501 (Ga 68 edotreotide) NDA
somatostatin receptor-positive neuroendocrine tumors (NETs)source ↗
Drug Pipeline Intelligence
B76
Pipeline Score $11.6B
Pipeline ValueValuation Signal
33
Drugs Scored5.8x
rNPV / MCap Top 96%
Small Cap (rank 37 of 911)
Percentile RankLantheus Holdings, Inc. holds a solid B-grade pipeline (76/100), with $17.8B risk-adjusted pipeline value, led by Perflutren Lipid microsphere in Chronic Kidney Diseases (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perflutren lipid microsphere Small molecule | Von-Hippel Lindau | Phase 2 | NCT03907657 | 16% | $3.2B | COMPLETED | 15 | - | - | Mar 13, 2023 | - | May 21, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
177Lu-PNT2002 Fast Track | metastatic castration-resistant prostate cancer | Phase 3 | 2024-09-15 | radiographic progression free survival: 9.5 months vs. 6.0 months; overall response rate: 38.1% vs. 12.0%; hazard ratio: 0.71; p value: 0.0088; patients halted therapy due to teae: 3.0% vs. 11.5% Read More | Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 Read More | |
177Lu-PNT2002 Fast Track | metastatic castration-resistant prostate cancer | Phase 3 | 2024-09-15 | radiographic progression free survival: 9.5 months vs. 6.0 months; overall response rate: 38.1% vs. 12.0%; hazard ratio: 0.71; p value: 0.0088; patients halted therapy due to teae: 3.0% vs. 11.5% Read More | Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 Read More | |
177Lu-PNT2002 Fast Track | metastatic castration-resistant prostate cancer | Phase 3 | 2024-09-15 | radiographic progression free survival: 9.5 months vs. 6.0 months; overall response rate: 38.1% vs. 12.0%; hazard ratio: 0.71; p value: 0.0088; patients halted therapy due to teae: 3.0% vs. 11.5% Read More | Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LNTH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LNTH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LNTHLantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
Lantheus Holdings, Inc. announced that it has received a Complete Response Letter from the FDA regarding its investigational product LNTH-2501 (Ga 68 edotreotide). This letter indicates that the FDA has not approved the product at this time, which may impact its future availability in the market. The company is expected to address the concerns raised by the FDA.
Read more →LNTHGoldman Sachs 47th Annual Global Healthcare Conference
The Goldman Sachs 47th Annual Global Healthcare Conference is scheduled for June 9, 2026, at 8:40 AM EDT. Attendees can listen to the event via webcast. Further details include options for printing the page and subscribing to RSS feeds for updates.
Read more →LNTHLantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Lantheus Holdings, Inc. announced that John Wiggins, Vice President of External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for 8:40 a.m. ET on June 9. The conference participation underscores Lantheus's commitment to improving patient outcomes through their innovative radiopharmaceutical solutions, which the company has provided for 70 years.
Read more →LNTHLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year
Lantheus Holdings, Inc. announced that its LNTH-2513 (18F-GP1) PET/CT imaging agent received the Image of the Year award from SNMMI at the 2026 Annual Meeting. This recognition highlights the agent's high diagnostic accuracy in detecting acute lower-extremity deep vein thrombosis (DVT) and its potential to improve thrombus visualization. The study demonstrated impressive sensitivity and specificity rates, along with a well-tolerated safety profile.
Read more →LNTHLantheus to Present at the William Blair 46th Annual Growth Stock Conference
Lantheus Holdings, Inc. announced that John Wiggins, Vice President of External Manufacturing, will speak at the William Blair 46th Annual Growth Stock Conference. The event is scheduled for June 3 at 12:10 p.m. ET. The company, dedicated to radiopharmaceuticals, aims to improve patient outcomes through innovative solutions. A live webcast of the presentation will be available on Lantheus's website, ensuring access for interested parties.
Read more →LNTHLantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
Lantheus Holdings, Inc. announced that it will present new radiodiagnostic data at the 2026 Society of Nuclear Medicine and Medical Imaging Annual Meeting in Los Angeles. The presentations will cover significant topics, including the impact of PSMA-PET with Piflufolastat F18 on prostate cancer management and the diagnostic performance of 18F-GP1 PET/CT for deep vein thrombosis. These advances aim to improve patient outcomes and demonstrate Lantheus' commitment to innovation in the radiopharmaceutical sector.
Read more →LNTHLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Lantheus Holdings, Inc. announced that it will present data at the 2026 ASCO Annual Meeting. The presentation will include a phase 1/2 study of LNTH-2403, a targeted monoclonal antibody for osteosarcoma. The meeting is scheduled for May 29 to June 2, 2026, in Chicago, IL.
Read more →LNTH▲ +5.6%on this news
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
Lantheus Holdings, Inc. reported a strong start to 2026 with revenues of $377.3 million, reflecting a 1.2% increase year-over-year. The company achieved FDA approval for PYLARIFY TruVu and received tentative approval for PNT2003. However, sales of PYLARIFY saw a decline, and operating income decreased significantly. The company reaffirmed its financial guidance for the year.
Read more →LNTHLantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. has scheduled its first quarter 2026 earnings conference call and webcast for May 7, 2026, at 8:00 a.m. ET. This event will focus on discussing the company's financial results and provide an update on business developments. Participants are encouraged to register online in advance to avoid delays. The company has a longstanding reputation in the radiopharmaceutical sector, providing products that enhance patient care.
Read more →LNTHLantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
Lantheus Holdings, Inc. announced that the FDA has extended the review period for the New Drug Application of LNTH-2501 (Ga 68 edotreotide) by three months, now targeting June 29, 2026. This extension is due to the FDA's need for additional information related to manufacturing. Importantly, the delay is not associated with safety or efficacy concerns. LNTH-2501 is designed for diagnosing somatostatin receptor-positive neuroendocrine tumors but remains unavailable for sale in the U.S.
Read more →LNTHLantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
Lantheus Holdings, Inc. announced FDA approval for PYLARIFY TruVu (piflufolastat F 18) injection, a new formulation of its PSMA PET imaging agent for prostate cancer. The improved formulation aims to enhance diagnostic performance, increase batch sizes, and support broader geographic availability. Expected to launch in the fourth quarter of 2026, PYLARIFY TruVu will provide more significant access to high-quality imaging for men with prostate cancer. The approval was supported by data from pivotal studies OSPREY and CONDOR, ensuring its safety and effectiveness.
Read more →LNTHLantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
Lantheus Holdings has received FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent to LUTATHERA, aimed at treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This marks a significant advancement in treatment options for patients. However, full approval is contingent upon the expiration of a 30-month stay related to patent litigation.
Read more →LNTHLantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Lantheus Holdings, Inc. reported strong financial results for Q4 and full year 2025, highlighting its market leadership with PYLARIFY and expansion through acquisitions. The company is focusing on PET radiodiagnostics and anticipates up to four FDA approvals in 2026. However, it faces uncertainties related to GAAP income guidance and integration of recent acquisitions.
Read more →LNTHLantheus to Present at March 2026 Investor Conferences
Lantheus Holdings, Inc. has announced that its Executive Chairperson and CEO, Mary Anne Heino, will present at upcoming investor conferences in March 2026. The company emphasizes its commitment to enhancing patient outcomes through its radiopharmaceutical solutions. Interested parties can access the live webcast of the presentations via the company's website.
Read more →LNTHLantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. announced a conference call scheduled for February 26, 2026, at 8:00 a.m. ET to discuss its financial results for Q4 and the full year of 2025. Participants are encouraged to register online in advance to avoid delays. A replay will be available shortly after the call.
Read more →LNTHLantheus Announces Closing of SPECT Business Sale to SHINE Technologies
Lantheus Holdings, Inc. has finalized the sale of its SPECT business to SHINE Technologies, allowing the company to concentrate on its expanding portfolio of PET radiodiagnostics and microbubbles. The transaction includes various diagnostic agents and manufacturing operations. This strategic move is expected to enhance Lantheus's focus on innovative radiopharmaceuticals.
Read more →LNTHLantheus to Present Florbetaben F 18 Data at CTAD 2025
Lantheus Holdings, Inc. will present new data on florbetaben F18 at the CTAD 2025 conference in San Diego. The poster presentation will focus on the binding of florbetaben to amyloid plaques, unaffected by certain amyloid-targeting antibodies. The conference is scheduled for December 1-4, 2025, with the presentation on December 3.
Read more →LNTHLANTHEUS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action – LNTH
Rosen Law Firm is reminding investors of Lantheus Holdings, Inc. about a lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Lantheus made misleading statements regarding its product Pylarify, particularly concerning its competitive pricing strategy. Investors are encouraged to secure counsel before the upcoming November 10 deadline to potentially recover damages incurred during the class period. The matter raises concerns about the company's transparency and market strategies.
Read more →LNTHLANTHEUS CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Stockholders to Contact the Firm Before November 10th Regarding Their Rights
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Lantheus Holdings, Inc. (LNTH) on behalf of investors who purchased securities between November 6, 2024, and August 6, 2025. The lawsuit alleges that Lantheus made materially false statements about its competitive position regarding its product, Pylarify. The firm is encouraging investors affected by these issues to contact them before the deadline of November 10, 2025, to discuss their legal rights and options. This legal action highlights serious concerns about the company's disclosure practices and market strategies.
Read more →LNTHLantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – LNTH
Lantheus Holdings, Inc. is currently facing a class action lawsuit for purported violations of securities laws. The complaint alleges that the company made misleading statements about the market performance of its product Pylarify, which has suffered significant sales declines. Shareholders are encouraged to contact the DJS Law Group for participation in the lawsuit, which spans buys made between February 26, 2025, and August 5, 2025. The deadline for joining the suit is November 10, 2025.
Read more →LNTH▼ -6.2%on this newsshared move
Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
Lantheus Holdings, Inc. announced its financial results for Q3 2025, highlighting strong performance and strategic advancements in radiopharmaceuticals. CEO Brian Markison expressed confidence in the company's future, especially regarding the PYLARIFY franchise and new PSMA PET formulation. The company is also undergoing a leadership transition as Markison plans to retire at the end of the year.
Read more →LNTH▼ -6.2%on this newsshared move
Lantheus Announces Leadership Transition Plan
Lantheus Holdings, Inc. announced the retirement of CEO Brian Markison, effective December 31, 2025, after over 13 years of service. Mary Anne Heino, former CEO, will serve as Executive Chairperson and interim CEO during the search for a new leader. The company aims to maintain strategic momentum and capitalize on its robust pipeline of products.
Read more →LNTH▼ -6.2%on this newsshared move
Lantheus Holdings, Inc. Class Action: Levi & Korsinsky Reminds Lantheus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 10, 2025 – LNTH
Levi & Korsinsky, LLP has announced a class action securities lawsuit against Lantheus Holdings, Inc. covering the period from February 26, 2025, to August 5, 2025. The lawsuit alleges that Lantheus made false statements and concealed crucial information about its revenue projections and market dynamics, particularly regarding its product Pylarify. Investors impacted by these alleged misrepresentations can seek to become lead plaintiffs until the deadline of November 10, 2025. No costs are required for class members to participate in the lawsuit.
Read more →LNTH▼ -6.2%on this newsshared move
LANTHEUS DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action – LNTH
Rosen Law Firm is urging investors of Lantheus Holdings, Inc. (NASDAQ: LNTH) who purchased securities between February 26, 2025, and August 5, 2025, to participate in a class action lawsuit with a lead plaintiff deadline set for November 10, 2025. The lawsuit alleges that Lantheus made materially false statements regarding its competitive position and pricing strategy for its product Pylarify. Investors may seek compensation without upfront fees through a contingency arrangement. The firm advises selecting experienced counsel to maximize potential recovery in the litigation.
Read more →LNTHLANTHEUS CLASS ACTION: Bragar Eagel & Squire, P.C. Urges Lantheus Investors to Contact the Firm Before November 10th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Lantheus Holdings, Inc. on behalf of investors who acquired securities between February 26, 2025, and August 5, 2025. The lawsuit alleges that the company made materially false statements and failed to disclose significant adverse information regarding its product, Pylarify. Investors have until November 10, 2025, to apply for lead plaintiff status. The firm encourages affected investors to reach out for more information about their legal rights.
Read more →LNTHLANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a reminder to investors of Lantheus Holdings, Inc. regarding a deadline related to a securities fraud class action lawsuit. The lawsuit alleges that the company made misrepresentations about its oncology product, Pylarify, which may have affected its competitive position. Investors who purchased shares between February 26 and August 5, 2025, are encouraged to assess their legal rights and options. A lead plaintiff is sought for the class action, and shareholders are urged to act by November 10, 2025, should they wish to participate.
Read more →LNTHLantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
Lantheus Holdings announced that the FDA has established a PDUFA date of March 29, 2026, for LNTH-2501, a diagnostic kit for PET imaging of somatostatin receptor-positive neuroendocrine tumors. This development aims to enhance diagnostic capabilities for clinicians treating NETs. If approved, LNTH-2501 will complement Lantheus' therapeutic candidate PNT2003.
Read more →LNTHLANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline
Lantheus Holdings, Inc. is facing a securities fraud class action lawsuit that pertains to its misrepresentation of the competitive position of its product, Pylarify. Investors who purchased shares between February 26, 2025, and August 5, 2025, should be aware of an upcoming deadline to potentially participate in the action. The deadline to file papers to serve as lead plaintiff is November 10, 2025. Bernstein Liebhard LLP, the law firm involved, is reminding affected shareholders of their rights and options.
Read more →LNTHLANTHEUS CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Investors of the November 10th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Lantheus Holdings, Inc. for securities fraud, affecting investors who purchased shares between February 26, 2025, and August 5, 2025. The lawsuit claims that the company made materially false statements while failing to disclose significant adverse facts about its product, Pylarify. Investors have until November 10, 2025, to apply to be lead plaintiffs in the case. The complaint highlights concerns over the company's pricing strategy and its potential impact on revenue and growth.
Read more →LNTHLantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
Lantheus Holdings announced that the FDA has accepted its New Drug Application for MK-6240, a PET imaging agent targeting tau in Alzheimer's disease. This agent aims to improve the detection of tau neurofibrillary tangles in patients with cognitive impairment. The FDA has set a target action date of August 13, 2026, for the application. MK-6240 has previously received Fast Track designation and is supported by data from two pivotal Phase 3 trials.
Read more →LNTHLANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) DEADLINE ALERT Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP is reminding investors of Lantheus Holdings, Inc. about an upcoming deadline regarding a securities fraud class action lawsuit. This case concerns accusations that the company misrepresented the competitive position of its oncology product, Pylarify. Investors who purchased shares between February 26, 2025, and August 5, 2025, may be eligible to participate in the lawsuit, with a filing deadline of November 10, 2025. The law firm operates on a contingency fee basis, meaning shareholders will not incur fees unless they win the case.
Read more →LNTHLANTHEUS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Lantheus Holdings Investors to Contact the Firm Before the November 10th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Lantheus Holdings, Inc. on behalf of investors who acquired securities during the class period from February 26 to August 5, 2025. The complaint alleges that the company made materially false statements concerning its product Pylarify, including issues related to its pricing strategy and market position. Investors have until November 10, 2025, to apply to be lead plaintiffs in the lawsuit. The law firm advises affected investors to contact them for legal support.
Read more →LNTHLantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. will host a conference call and webcast on November 6, 2025, at 8:00 a.m. ET to discuss its third-quarter financial results and provide a business update. Participants can register online to access the call, and a replay will be available shortly after the event. Lantheus has been a leader in radiopharmaceutical solutions for nearly 70 years.
Read more →LNTHLANTHEUS CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Lantheus Holdings Investors of the November 10th Deadline in the Filed Class Action Lawsuit
A class action lawsuit has been initiated against Lantheus Holdings, Inc., with allegations concerning misleading statements made by the company's executives regarding the competitive positioning of its product, Pylarify. The lawsuit, filed in the Southern District of New York, covers the period from February 26, 2025, to August 5, 2025. Investors have until November 10, 2025, to apply to be lead plaintiffs. The claim points to serious oversights in the company's pricing strategy and market assessment, suggesting that this has impacted the true state of the company's financial health and outlook.
Read more →LNTHLantheus Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before November 10, 2025 to Discuss Your Rights – LNTH
Lantheus Holdings, Inc. is currently embroiled in a class action securities lawsuit initiated by Levi & Korsinsky, LLP, targeting alleged securities fraud that affected investors between February 26, 2025 and August 5, 2025. The lawsuit claims that Lantheus provided misleading information regarding its revenue projections and competitive positioning in the market for its product, Pylarify. Investors have been urged to contact the law firm by November 10, 2025, if they believe they have incurred losses due to these alleged misrepresentations. Levi & Korsinsky assert that they have significant experience in securities litigation, offering no-cost participation to affected investors.
Read more →LNTHLANTHEUS DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Lantheus Holdings Investors to Contact the Firm Before the November 10th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Lantheus Holdings (LNTH) concerning securities bought between February 26, 2025, and August 5, 2025. The lawsuit alleges that the company misled investors about its product Pylarify and its market position. Investors are encouraged to apply to be lead plaintiffs before the November 10th deadline, as the complaint states that Lantheus concealed material adverse information regarding pricing dynamics and competitive threats. The firm is actively seeking individuals who suffered losses during this period to come forward.
Read more →LNTHLANTHEUS ALERT: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Before the November 10th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Lantheus Holdings, Inc. for alleged misleading statements made by the company from February 26 to August 5, 2025. The lawsuit claims that Lantheus failed to disclose material adverse facts regarding its product Pylarify's competitive standing and pricing dynamics. Investors affected by these allegations are encouraged to contact the law firm before the November 10, 2025 deadline to be appointed as lead plaintiff. The firm emphasizes there is no cost involved in seeking their legal assistance.
Read more →LNTHLantheus Holdings, Inc. (LNTH) Investors: November 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Lantheus Holdings, Inc. is facing a securities class action lawsuit filed by the law firm Kessler Topaz Meltzer & Check, LLP. The suit is on behalf of investors who acquired Lantheus securities between February 26, 2025, and August 5, 2025. Allegations include false or misleading statements regarding PYLARIFY's competitive positioning and a problematic price increase. Investors have until November 10, 2025, to seek lead plaintiff status in the case.
Read more →LNTHLANTHEUS DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Lantheus Holdings Investors of the November 10th Deadline in the Class Action Lawsuit
A class action lawsuit has been filed against Lantheus Holdings, Inc. (LNTH) alleging that the company misled investors about the true competitive position of its product, Pylarify. The complaint claims Lantheus provided overly optimistic statements while failing to disclose critical information regarding pricing and competition dynamics. Investors who acquired securities between February 26, 2025, and August 5, 2025, have until November 10, 2025, to apply for lead plaintiff status in the lawsuit. This legal action highlights significant concerns regarding Lantheus' operational transparency and its impact on stockholder interests.
Read more →LNTHLANTHEUS CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors to Contact the Firm regarding a Class Action Lawsuit Filed Against Lantheus Holdings, Inc.
A class action lawsuit has been initiated against Lantheus Holdings, Inc. for alleged misleading statements made during the period from February 26, 2025, to August 5, 2025. The lawsuit accuses the company's defendants of providing overly positive information while failing to disclose significant adverse facts regarding the competitive position of their product, Pylarify. Investors impacted by these claims are encouraged to contact the law firm Bragar Eagel & Squire for options. The deadline for affected investors to apply to be lead plaintiffs is November 10, 2025.
Read more →LNTHLANTHEUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Lantheus Holdings, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Lantheus Holdings, Inc., pertaining to the period between February 26, 2025, and August 5, 2025. The lawsuit alleges that Lantheus made misleading statements regarding the competitive position of its product Pylarify, as well as its pricing strategy. Investors are encouraged to contact the firm for more information or to participate in the action. The deadline for investors to apply to be lead plaintiff is November 10th, 2025.
Read more →LNTHLantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
Lantheus Holdings and GE HealthCare have entered into an exclusive licensing agreement for the development and commercialization of PYLARIFY (piflufolastat F18) in Japan. This partnership aims to enhance prostate cancer diagnostics through GE HealthCare's established manufacturing and R&D capabilities. The agreement includes financial arrangements and the formation of a Joint Steering Committee to oversee the project.
Read more →LNTHLANTHEUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Lantheus Holdings, Inc. on Behalf of Lantheus Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Lantheus Holdings, Inc. on behalf of stockholders who may have suffered losses. The law firm is evaluating claims related to potential violations of federal securities laws. This investigation follows Lantheus's recent announcement of disappointing second quarter results, including a stark decline in revenues and lowered earnings guidance for the year. The stock price fell significantly after these results were disclosed, prompting legal scrutiny from the firm.
Read more →LNTHLantheus Holdings, Inc. Class Action: The Gross Law Firm Reminds Lantheus Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 10, 2025 – LNTH
Lantheus Holdings, Inc. is facing a class action lawsuit, with a lead plaintiff deadline set for November 10, 2025. The complaint alleges that the company made misleading statements regarding its projected revenue and the growth potential of its product, Pylarify. It accuses Lantheus of not accurately understanding the competitive landscape and pricing dynamics affecting its market. Shareholders are encouraged to register to participate in the lawsuit, which involves no costs to them.
Read more →LNTHLantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Lantheus Holdings, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9. CEO Brian Markison will lead the presentation, which can be accessed via the company's website. A replay will be available for 30 days post-event, showcasing Lantheus's commitment to radiopharmaceutical advancements.
Read more →LNTH▼ -28.6%on this news
Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update
Lantheus Holdings, Inc. reported its second-quarter financial results for 2025, highlighting strategic acquisitions and FDA progress. The company completed acquisitions of Evergreen Theragnostics and Life Molecular Imaging, aiming to enhance its radiopharmaceutical capabilities. Despite facing competition impacting PYLARIFY, Lantheus announced a new stock repurchase program and received FDA acceptance for a new PSMA PET formulation.
Read more →LNTH▼ -28.6%on this newsshared move
Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent
Lantheus Holdings, Inc. announced the FDA's acceptance of a New Drug Application for a new formulation of its PSMA PET imaging agent, PYLARIFY. The new formulation aims to increase batch size by approximately 50%, enhancing patient access and maintaining high diagnostic performance. The PDUFA date is set for March 6, 2026, marking a significant step in advancing prostate cancer imaging.
Read more →LNTHLantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. has announced it will host a conference call and webcast on August 6, 2025, at 8:00 a.m. Eastern Time to discuss its financial results for the second quarter of 2025. Participants are encouraged to register in advance to avoid delays. A replay of the call will be available shortly after its conclusion and archived for 30 days. This event highlights Lantheus's commitment to transparency and investor engagement.
Read more →LNTHLantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D
Lantheus Holdings, Inc. has successfully completed its acquisition of Life Molecular Imaging Ltd. This acquisition appoints Dr. Ludger Dinkelborg as the new Head of Research and Development, effective August 1, 2025. The integration provides Lantheus access to Neuraceq, a PET imaging agent for Alzheimer's disease. While the acquisition is viewed positively for expanding Lantheus's pipeline, there are inherent risks associated with the use of Neuraceq, particularly around image interpretation and radiation exposure.
Read more →LNTHLantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
Lantheus Holdings, Inc. announced the presentation of new data at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, highlighting its oncology radiodiagnostic agents. Presentations will focus on advancements in the production and quality control of these agents and their applications in cancer imaging. Lantheus aims to demonstrate the clinical advantages of its products, such as the widely used PYLARIFY imaging agent, contributing to better patient outcomes. The annual meeting will take place from June 21-24, 2025, in New Orleans, LA.
Read more →LNTHLantheus to Present at the 2025 Truist Securities MedTech Conference
Lantheus Holdings, Inc. (NASDAQ: LNTH), a prominent company in radiopharmaceuticals, announced that its CEO Brian Markison will present at the 2025 Truist Securities MedTech Conference. The presentation is scheduled for June 17 at 8:40 a.m. ET. Interested parties can access the live webcast through the Company's website, where a replay will also be available for 30 days post-event. This participation highlights Lantheus's ongoing commitment to advancing disease management and patient care.
Read more →LNTHLantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Lantheus Holdings, Inc. will have its CEO Brian Markison present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. This event will take place at 2:40 p.m. ET and will be accessible via a live webcast. Following the presentation, a replay will be available on the company's website for at least 30 days. Lantheus specializes in radiopharmaceuticals and has a significant history in the field.
Read more →LNTH▼ -23.2%on this news
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update Worldwide revenue of $372.8 million in the first quarter 2025 GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the fi
Lantheus Holdings, Inc. reported its first quarter 2025 financial results, revealing a slight revenue increase to $372.8 million. Despite the revenue growth, key metrics such as net income and GAAP earnings per share fell significantly compared to the same period last year. The company successfully completed the acquisition of Evergreen Theragnostics, aiming to bolster its portfolio. Additionally, Lantheus announced encouraging clinical data for MK-6240 and outlined its revenue and earnings guidance for the full year 2025.
Read more →LNTHLantheus Announces Sale of SPECT Business to SHINE Technologies
Lantheus Holdings, Inc. has announced the sale of its SPECT business to SHINE Technologies in order to focus on its innovative PET radiodiagnostics and radiopharmaceutical pipeline. The agreement includes the transfer of various diagnostic products and facilities, which will allow Lantheus to enhance its position in the market. This strategic move follows previous acquisitions and is expected to benefit both companies and their employees. The transaction has been approved and is scheduled to close by the end of the year, pending customary conditions.
Read more →LNTHLantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies
Lantheus Holdings announced that its radiodiagnostic agent MK-6240 successfully met primary endpoints in two pivotal studies, showcasing its sensitivity and specificity. This achievement positions MK-6240 as a promising diagnostic tool for Alzheimer’s disease, with an NDA submission planned for the third quarter of 2025. The results are expected to enhance diagnostic confidence and improve patient management. However, the approval process may face uncertainties, including potential regulatory delays and market acceptance challenges.
Read more →LNTHLantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. announced a conference call and webcast to discuss its first quarter 2025 financial and operational results. Scheduled for May 7, 2025, at 8:00 a.m. Eastern Time, the call reflects the company's commitment to transparency with its stakeholders. Attendees are encouraged to register online to ensure a smooth experience. Lantheus has a long-standing presence in the radiopharmaceutical sector, focused on improving patient outcomes through advanced science.
Read more →LNTHLantheus Completes Acquisition of Evergreen Theragnostics
Lantheus Holdings, Inc. has successfully completed the acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. This acquisition includes OCTEVY, a PET diagnostic imaging agent for neuroendocrine tumors, and strengthens Lantheus's position across the radiopharmaceutical value chain. The CEO emphasized the strategic importance of this acquisition for enhancing innovation and improving patient outcomes. However, the company also acknowledged risks associated with integration and regulatory approval processes.
Read more →LNTH▲ +16.5%on this news
Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024 Free cash flow was $141.4 million and $493.1 millio
Lantheus Holdings, Inc. reported a strong financial performance for the fourth quarter and full year 2024, with worldwide revenue reaching $391.1 million and $1.53 billion respectively. PYLARIFY, its flagship radiodiagnostic product, achieved blockbuster status. Despite a decrease in net income and earnings per share, the company reported significant growth in cash flow and revenue. Looking ahead, Lantheus announced plans for diversification through strategic acquisitions and a focus on the development of early and late-stage assets aimed at enhancing patient outcomes and shareholder value.
Read more →LNTHLantheus to Present at Upcoming Investor Conferences
Lantheus Holdings, Inc. has announced that members of its management team will be presenting at various upcoming investor conferences including B. Riley Securities Precision Oncology & Radiopharma Day and the TD Cowen 45th Annual Health Care Conference. These events will provide opportunities for stakeholders to engage with the company's leadership and gain insights into their ongoing commitments in the radiopharmaceutical field. Lantheus emphasizes its goal of improving patient outcomes by enabling clinicians to better detect and treat diseases.
Read more →LNTHLantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. announced that it will host a conference call and webcast on February 26, 2025, at 8:00 a.m. ET. The purpose of this event is to discuss the company's financial and operating results for the fourth quarter and the full year of 2024. Participants are encouraged to register ahead of the start time to ensure a smooth experience. The company has a long-standing focus on radiopharmaceuticals, which has been a core aspect of its operations for over 65 years.
Read more →LNTHLantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting
Lantheus Holdings, Inc. has announced that data regarding PYLARIFY (piflufolastat F 18) will be presented at the upcoming 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. The presentations will focus on PYLARIFY's role in detecting recurrent prostate cancer and its effectiveness based on real-world evidence. Despite showing significant diagnostic capabilities, the product carries risks of imaging misinterpretation and is influenced by PSA levels and other patient-specific factors.
Read more →LNTHLantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member
Lantheus Holdings, Inc. announces the appointment of Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025. Dr. Morrow, an experienced pharmaceutical executive with a strong background in oncology, will serve on the Board's Science and Technology Committee. This adds to Lantheus' efforts to grow and innovate within the radiopharmaceutical field, following the recent announcement of two strategic deals. The appointment reflects Lantheus' ongoing commitment to advancing patient outcomes through enhanced leadership and expertise.
Read more →LNTH▼ -7.3%on this newsshared move
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader Advances radiopharmaceutical leadership with addition of scala
Lantheus Holdings, Inc. has announced its acquisition of Evergreen Theragnostics for an upfront payment of $250 million, potentially reaching $1 billion including milestone payments. This acquisition aims to strengthen Lantheus’s position as a fully integrated leader in the radiopharmaceutical sector, bolstering its capabilities in manufacturing and clinical development. The deal includes the addition of OCTEVY, a diagnostic asset for neuroendocrine tumors, which complements Lantheus’s therapeutic candidate, PNT2003. The transaction is expected to close in the second half of 2025, pending regulatory approvals.
Read more →LNTHLantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer s Disease Radiodiagnostic Market Enhances Lantheus growth profile with Neur
Lantheus Holdings, Inc. has announced its acquisition of Life Molecular Imaging for $350 million, aimed at boosting its position in the Alzheimer's disease radiodiagnostic market. The deal includes additional potential earnings of up to $400 million through earn-outs and milestones. This strategic move is expected to enhance Lantheus's near and long-term growth profile with the integration of Neuraceq, a PET imaging agent for Alzheimer's diagnostics. The transaction is anticipated to close in the second half of 2025, pending regulatory approvals.
Read more →LNTHLantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
Lantheus Holdings Inc. has increased its shareholding in Radiopharm Theranostics to 12.16% through a private placement of US$5 million (A$8 million). The placement involved 133 million shares at A$0.060 per share, which represents a 150% premium to Radiopharm's last closing price. This funds raised will be used to further develop Radiopharm's clinical pipeline in oncology radiopharmaceuticals. Both companies express excitement about their ongoing collaboration in clinical development.
Read more →LNTH▲ +8.8%on this news
Lantheus Announces Share Repurchase Program
Lantheus Holdings, Inc. has announced a new share repurchase program authorized by its board of directors. The company plans to repurchase up to $250 million of its common stock over the next twelve months, showcasing confidence in its financial position and commitment to shareholder value. The repurchases are expected to commence in the fourth quarter and will be conducted based on market conditions and regulatory guidelines. Lantheus continues to focus on expanding its radiopharmaceutical portfolio while enhancing returns for shareholders.
Read more →LNTH▼ -6.3%on this news
Lantheus to Present at the Jefferies London Healthcare Conference
Lantheus Holdings, Inc. announced that Chief Financial Officer Bob Marshall will present at the Jefferies London Healthcare Conference on November 20, 2024. This event showcases Lantheus's commitment to the field of radiopharmaceuticals and its focus on improving patient outcomes. Attendees can access a live webcast of the presentation through the company's website, with a replay available for 30 days afterward. Lantheus has been delivering radiopharmaceutical solutions for over 65 years.
Read more →LNTHLantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
Lantheus Holdings, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) updated payment rates for diagnostic radiopharmaceuticals under the 2025 Medicare Hospital Outpatient Prospective Payment System. The company praised these changes for ensuring broader patient access and improving reimbursement rates for innovative products. PYLARIFY, its leading product, is expected to surpass $1 billion in sales for 2024, reinforcing its status as the top PSMA PET imaging agent in the U.S. The new OPPS rules will take effect on January 1, 2025.
Read more →LNTH▼ -20.7%on this newsshared move
Lantheus Reports Third Quarter 2024 Financial Results Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023 GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quart
Lantheus Holdings, Inc. reported a successful financial performance for the third quarter of 2024, boasting worldwide revenue of $378.7 million, an increase of 18.4% from the same quarter in 2023. Adjusted fully diluted earnings per share rose to $1.70, marking a 15.6% increase. However, GAAP earnings per share slightly declined to $1.79 from $1.88 in the previous year. The company announced an expansion of its Alzheimer's diagnostics portfolio and praised new CMS payment guidelines improving access to its radiopharmaceuticals.
Read more →LNTH▲ +6.9%on this news· ran to -18% by day 3shared move
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
Lantheus Holdings, Inc. has welcomed the final rule from the Centers for Medicare & Medicaid Services (CMS) for 2025, which enhances payment structures for specialized diagnostic radiopharmaceuticals. This new rule allows for unbundled payments for radiopharmaceuticals that cost over $630 per day, facilitating greater patient access. The change supports the use of PYLARIFY, an important imaging agent for prostate cancer, and is seen as a significant step towards equitable healthcare and further innovation in the industry. The rule will take effect on January 1, 2025.
Read more →LNTHLantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. announced it will host a conference call and webcast to discuss its third-quarter financial results on November 6, 2024, at 8:00 a.m. ET. Interested participants are encouraged to register in advance online. Following the live event, a replay will be accessible for 30 days on the company's website. This call underscores the company's commitment to keeping stakeholders informed about its performance and operational achievements.
Read more →LNTHLantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
Lantheus Holdings presented promising results from the SPLASH Phase 3 trial, which evaluated the efficacy of 177Lu-PNT2002 in patients with metastatic castration-resistant prostate cancer. The study achieved its primary endpoint, showing significant improvements in radiographic progression-free survival and overall response rates compared to the control arm. Additionally, patients receiving the treatment exhibited better health-related quality of life measures. The results were shared at the ESMO Congress 2024, emphasizing the potential of PSMA-targeted radioligand therapies for advanced prostate cancer patients.
Read more →LNTHLantheus Appoints Julie Eastland as New Board Member
Lantheus Holdings has appointed Julie Eastland as a new member of its Board of Directors, effective September 3, 2024. Eastland, who has significant experience in biotechnology and finance, will also be a member of the Board's Audit Committee. Her expertise in strategic planning and operational success is expected to contribute positively to Lantheus's ongoing innovations in radiopharmaceuticals. This expands the board to ten directors, with a strong independent presence aimed at guiding the company's future initiatives in improving patient care.
Read more →LNTHLantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Lantheus Holdings, Inc. has announced that its CEO, Brian Markison, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. The presentation will highlight Lantheus's focus on radiopharmaceuticals aimed at improving patient outcomes. Investors and interested parties can access the live webcast via the company's website, with a replay available for 30 days following the event. The company, headquartered in Massachusetts, has a long history in providing radiopharmaceutical solutions.
Read more →LNTHLantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
Lantheus Holdings, Inc. will present new clinical data from the Phase 3 SPLASH trial on September 15, 2024, at the ESMO Annual Meeting in Barcelona. The trial focuses on the efficacy of 177Lu-PNT2002, a radioligand therapy for patients with PSMA-positive metastatic castration-resistant prostate cancer. This therapy previously received Fast Track designation from the FDA, indicating its potential significance in addressing unmet needs in cancer treatment. However, the final outcomes of the trial and subsequent regulatory approvals remain uncertain.
Read more →LNTHLantheus Reports Second Quarter 2024 Financial Results Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pi
Lantheus Holdings, Inc. reported its financial results for the second quarter of 2024, highlighting a significant revenue increase to $394.1 million, driven largely by its products PYLARIFY and DEFINITY. The company completed three strategic transactions aimed at expanding its innovative pipeline in radiopharmaceuticals. However, GAAP earnings per share decreased compared to the previous year, alongside a notable drop in net income. Despite these challenges, the company maintained its revenue guidance for the full year and presented optimistic prospects for future growth in the radiopharmaceutical market.
Read more →LNTHLantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. has announced it will host a conference call and webcast on July 31, 2024, at 8:00 a.m. ET to discuss its second quarter financial and operational results for the year. The company encourages participants to register online in advance. A replay of the event will be made available for at least 30 days after the live broadcast. Lantheus is recognized for its long-standing commitment to delivering innovative radiopharmaceutical solutions.
Read more →LNTH▲ +36.7%on this news· ran to +59% by day 1
Lantheus Welcomes CMS’ Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
Lantheus Holdings, Inc. expressed support for the Centers for Medicare & Medicaid Services' proposed Medicare payment reforms scheduled for 2025, aiming to enhance reimbursement for specialized diagnostic radiopharmaceuticals. This proposed change would allow diagnostic radiopharmaceuticals such as PYLARIFY to be reimbursed separately, potentially improving patient access. The proposal includes a 60-day comment period, after which a final rule will be issued, with implementation expected to begin on January 1, 2025. Lantheus is committed to collaborating with stakeholders to advocate for these changes, emphasizing the importance of equitable access for advanced diagnostic tools in cancer care.
Read more →LNTHLantheus Appoints Jamie Spaeth as Chief People Officer
Lantheus Holdings, Inc. has appointed Jamie Spaeth as Chief People Officer, enhancing their executive team. This decision aligns with their commitment to foster a collaborative culture aimed at better patient outcomes. Spaeth brings nearly 20 years of HR experience in the biotechnology and pharmaceutical sectors, previously leading HR efforts at Corium and Sage Therapeutics. Her appointment is expected to elevate Lantheus's organizational culture and support the company's strategic goals in delivering innovative healthcare solutions.
Read more →LNTHLantheus Acquires Global Rights to Life Molecular Imaging s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers Deal Further Strengthens Lantheus Prostate Cancer Portfolio and Expands Pip
Lantheus Holdings, Inc. has acquired the global rights to Life Molecular Imaging's RM2, a novel therapeutic and diagnostic pair targeting the gastrin-releasing peptide receptor for prostate and breast cancers. This acquisition, which includes an upfront payment of $35 million and potential royalties, aims to enhance Lantheus' prostate cancer portfolio while also expanding its capabilities to address breast cancer. The development of 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 will proceed with plans for a Phase 1/2a study in prostate cancer patients starting in 2025. This initiative represents a significant step forward in addressing unmet needs in oncological care.
Read more →LNTHLantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform
Lantheus Holdings has announced the integration of its AI-enabled software aPROMISE on Siemens Healthineers' syngo.via platform. This FDA-cleared device software enhances the analysis of PSMA PET/CT images, offering significant insights into total disease burden for prostate cancer patients. The upcoming demonstration at the Society of Nuclear Medicine and Molecular Imaging event signifies its importance in clinical applications. The integration is expected to streamline workflows in nuclear medicine across PET facilities in the U.S.
Read more →LNTHLantheus to Present at the William Blair 44th Annual Growth Stock Conference
Lantheus Holdings, Inc. has announced that its President, Paul Blanchfield, will present at the William Blair 44th Annual Growth Stock Conference. The presentation is scheduled for June 4 at 2:40 p.m. CT and can be accessed via a live webcast on the company's website. Lantheus is recognized for its commitment to enhancing clinical outcomes through advanced radiopharmaceuticals and has a substantial history of over 65 years in the industry.
Read more →LNTHLantheus Announces Executive Appointments to Accelerate Innovation Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer
Lantheus has announced the appointments of Jeffrey S. Humphrey, MD, as Chief Medical Officer and Jean-Claude Provost, MD, as Chief Science Officer, effective May 28, 2024. These appointments aim to accelerate innovation within the company, which is focused on radiopharmaceuticals. Dr. Humphrey's extensive clinical oncology experience and Dr. Provost's knowledge in radiopharmaceutical development are expected to contribute significantly to Lantheus's goals in enhancing its pipeline and capabilities. Both executives hold substantial industry experience and educational credentials in their respective fields.
Read more →LNTH▲ +16%on this news
Lantheus Reports First Quarter 2024 Financial Results First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 GAAP fully diluted net income per share of $1.87, compared to GAA
Lantheus Holdings reported a strong financial performance for the first quarter of 2024, with worldwide revenue reaching $370 million, a 23% increase from the previous year. The company achieved a GAAP fully diluted net income per share of $1.87, contrasting with a net loss per share in the same quarter last year. Additionally, Lantheus raised its revenue and earnings guidance for the full year 2024, signaling confidence in continued growth. The positive results were driven largely by increased sales of their products, particularly PYLARIFY and DEFINITY.
Read more →LNTHLantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. is set to host its first quarter 2024 earnings conference call and webcast on May 2, 2024, at 8:00 a.m. Eastern Time. The session aims to discuss the company's financial and operating results. Participants are encouraged to register online in advance to avoid delays, and a replay will be made available shortly after the event. Lantheus has a strong history in the radiopharmaceutical sector, contributing to improved patient care.
Read more →LNTHLantheus to Present at the Leerink Partners Global Biopharma Conference 2024
Lantheus Holdings, Inc. announced that President Paul Blanchfield will present at the Leerink Partners Global Biopharma Conference 2024 on March 12, 2024. This event showcases the company's ongoing commitment to delivering radiopharmaceutical solutions. The presentation is intended to inform investors and stakeholders about Lantheus's advancements in disease management. A live webcast will be available, with a replay accessible for 30 days post-event.
Read more →LNTHLantheus Announces the FDA Approval of DEFINITY (Perflutren Lipid Microsphere) for Pediatric Patients
Lantheus Holdings, Inc. has announced FDA approval for DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for pediatric patients. This approval allows for improved diagnostic imaging in children with suboptimal echocardiograms. Clinical studies confirm DEFINITY's efficacy and safety in pediatric populations, providing a crucial tool for healthcare professionals. However, there are noted risks associated with hypersensitivity and cardiopulmonary reactions that healthcare providers need to consider.
Read more →LNTHLantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
Lantheus Holdings, Inc. has announced the promotion of Amanda Morgan to Chief Commercial Officer, effective March 25, 2024. With over 20 years of experience in the healthcare industry, Morgan has been pivotal in driving the company's commercial strategy and operations. As CCO, she aims to enhance collaboration within the team and advance Lantheus' product portfolio with a patient-centric approach. This promotion is viewed as a strategic move to strengthen Lantheus' position in a competitive market.
Read more →LNTHLantheus to Present at the TD Cowen 44th Annual Health Care Conference
Lantheus Holdings, Inc. will present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024, at 10:30 a.m. ET. Paul Blanchfield, the company's President, will lead the presentation. Interested parties can access the live webcast through the Investors section of Lantheus' website, with a replay available for 30 days following the event. Lantheus is known for its innovative radiopharmaceutical solutions aimed at improving patient outcomes.
Read more →LNTH▲ +14.7%on this newsshared move
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023 GAAP net income of $103.4 million and $326.7 million for
Lantheus Holdings, Inc. reported strong financial results for the fourth quarter and full year of 2023, demonstrating significant growth in revenues and net income compared to the prior year. The company achieved $354 million in revenue for Q4 2023, a 34.5% increase from Q4 2022, and full year revenues totaled $1.3 billion, up 38.6% year over year. The GAAP net income for Q4 2023 was $103.4 million, a notable improvement from a loss in the same quarter the previous year. Looking forward, Lantheus has provided guidance for revenue and adjusted earnings per share for 2024, highlighting expectations for continued growth.
Read more →LNTHLantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
Lantheus Holdings, Inc. announced a collaboration with the National Institute on Aging for the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI). This collaboration allows the use of MK-6240, a PET imaging agent targeting tau tangles in Alzheimer’s disease. The study will involve 37 Alzheimer’s Disease Research Centers across the U.S., with a goal of recruiting 2,000 subjects to collect imaging and biomarker data. This initiative aims to enhance the understanding of dementia and advance treatment avenues.
Read more →LNTHLantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. has announced that it will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results. The event is scheduled for February 22, 2024, at 8:00 a.m. Eastern Time. Participants can register online for the call, which highlights the company’s commitment to transparency and communication with stakeholders. A replay will be available shortly after the event, ensuring accessibility to the information.
Read more →LNTHLantheus Announces CEO Succession Plan
Lantheus Holdings has announced the appointment of Brian Markison as the new Chief Executive Officer, effective March 1, 2024, following Mary Anne Heino's retirement. Heino will take on the role of Chair of the Board of Directors after a successful nine-year leadership. Under her guidance, Lantheus has achieved notable growth, including a revenue increase of approximately 38-39% in 2023. Markison, an experienced industry veteran with a strong background in oncology and diagnostics, is expected to lead the company into its next growth phase.
Read more →LNTHLantheus Announces CEO Succession Plan Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective
Lantheus Holdings, Inc. has appointed Brian Markison as its new CEO, effective March 1, 2024, succeeding Mary Anne Heino, who will transition to Chair of the Board. Markison, a seasoned executive with 40 years in healthcare, has been a board member since 2012 and serves as Executive Chair until his official appointment. Under Heino's leadership, Lantheus saw significant growth, including advancements in radiopharmaceuticals. The company reported preliminary revenues for 2023 between $1.295 and $1.297 billion, reflecting robust growth compared to the previous year.
Read more →LNTHLantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA (Lutetium Lu 177 Dotatate)
Lantheus Holdings, Inc. announced the acceptance of its ANDA for Lutetium Lu 177 Dotatate, a generic version of LUTATHERA, by the FDA. This marks a significant step in the company's strategy to improve patient outcomes for GEP-NETs. Lantheus believes it is the first applicant to submit a complete ANDA under the Hatch-Waxman Act, which could qualify them for 180 days of generic exclusivity upon approval. The company aims to leverage this opportunity in the radiopharmaceutical market.
Read more →LNTHLantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
Lantheus Holdings, Inc. has entered into strategic agreements with Perspective Therapeutics to expand its oncology pipeline. The deal includes options for exclusive licensing and co-development of promising alpha therapies for neuroendocrine and prostate cancers, alongside a substantial equity investment. As part of the collaboration, Perspective will acquire Lantheus's radiopharmaceutical manufacturing facility in Somerset, NJ. The partnerships are designed to enhance treatment options in precision oncology, although they are subject to certain closing conditions and regulatory approvals.
Read more →LNTHLantheus Reports Preliminary Fiscal Year 2023 Revenue Full year 2023 worldwide revenue expected to be in the range of $1.295 - 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR miles
Lantheus Holdings, Inc. has reported preliminary unaudited revenue results for the fiscal year 2023, anticipating global revenue between $1.295 and $1.297 billion, representing a significant increase of 38-39% from the previous year. PYLARIFY revenue is projected to grow by 61-62%, while DEFINITY is expected to rise by 14%. The company attributes this success to its commitment to delivering life-changing radiopharmaceutical solutions. Final financial results and guidance for 2024 will be disclosed in February 2024.
Read more →LNTHLantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Lantheus Holdings, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 11:15 a.m. PST. The presentation will be led by CEO Mary Anne Heino. Interested parties can access the live webcast through the company's website, with a replay available for 30 days post-presentation. Lantheus continues to focus on delivering innovative radiopharmaceutical solutions to improve patient outcomes.
Read more →LNTH▼ -26.9%on this news
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Lantheus Holdings and POINT Biopharma have reported positive topline results from their phase 3 SPLASH trial, which evaluated the radioligand therapy 177Lu-PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial met its primary endpoint with 177Lu-PNT2002 showing a median radiographic progression-free survival of 9.5 months. The treatment also demonstrated a favorable safety profile compared to the control arm. While the results indicate promising efficacy, interim overall survival data were not fully mature, and a significant number of control patients crossed over to the treatment arm.
Read more →LNTH▼ -5.9%on this news
Lantheus Reports Third Quarter 2023 Financial Results Worldwide revenue of $319.9 million for the third quarter 2023, representing an increase of 33.7% from the prior year period GAAP net income of $132.0 million for the
Lantheus Holdings, Inc. reported strong financial results for the third quarter of 2023, with worldwide revenue reaching $319.9 million, marking a 33.7% increase compared to the previous year. The company also reported a GAAP net income of $132.0 million, significantly up from $61.2 million in the same quarter last year. In addition, Lantheus updated its full-year revenue guidance, projecting revenues between $1.255 billion and $1.27 billion. CEO Mary Anne Heino emphasized the company's progress in their commercial portfolio and pipeline during the quarter.
Read more →LNTHLantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. has announced it will host a conference call and webcast to discuss its third quarter financial and operational results on November 2, 2023, at 8:00 a.m. Eastern Time. The company encourages participants to register in advance to avoid delays. Following the call, a replay will be made available for 30 days on their investor relations webpage. Lantheus is known for its dedication to enhancing patient care through innovative treatments and technologies.
Read more →LNTHLantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
Lantheus Holdings, Inc. announced the presentation of PYLARIFY AI data at the 2023 European Association of Nuclear Medicine Annual Meeting, scheduled for September 9-13, 2023, in Vienna, Austria. The PYLARIFY AI is an FDA-cleared software that standardizes PSMA PET reporting, greatly aiding in tracking and managing prostate cancer. The presentation will be given by an Assistant Professor from UCLA, showcasing the latest developments in prostate cancer staging. Lantheus aims to enhance patient outcomes through advanced diagnostics and AI technologies.
Read more →LNTHLantheus to Present at the Wells Fargo Healthcare Conference
Lantheus Holdings, Inc. will present at the Wells Fargo Healthcare Conference on September 7, 2023, at 9:30 a.m. ET. The company's leadership, including President Paul Blanchfield and CFO Bob Marshall, will discuss its commitment to improving patient outcomes. Lantheus focuses on diagnostics, radiotherapeutics, and artificial intelligence to aid clinicians in managing disease. A live webcast of the presentation will be available on their website, with a replay accessible for 30 days post-event.
Read more →LNTH▼ -10.7%on this news
Lantheus Announces Agreement to Sell RELISTOR Royalties to HealthCare Royalty
Lantheus Holdings, Inc. announced the sale of its RELISTOR royalties to HealthCare Royalty, a move aligned with its long-term growth strategy focused on radiopharmaceuticals. The company aims to reinvest the proceeds, starting with an initial payment of approximately $98 million, to bolster its innovative pipeline and ongoing therapeutic programs. This strategic divestiture allows Lantheus to improve operational focus and financial flexibility. Under the agreement, Lantheus also retains rights to future milestone payments depending on RELISTOR's performance.
Read more →LNTH▼ -10.7%on this news
Lantheus Reports Second Quarter 2023 Financial Results Worldwide revenue of $321.7 million for the second quarter 2023, representing an increase of 43.8% from the prior year period GAAP net income of $94.1 million for th
Lantheus Holdings, Inc. reported a robust second quarter for 2023, with a 43.8% increase in worldwide revenue, amounting to $321.7 million, and a notable rise in GAAP net income to $94.1 million. The company achieved an adjusted fully diluted net income per share of $1.54, a substantial improvement from $0.89 in the previous year. However, Lantheus reported negative free cash flow of $43 million and significant cash used in operating activities. The company has increased its revenue and earnings guidance for the upcoming third quarter, indicating a positive outlook for the remainder of the year.
Read more →LNTHLantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. has announced a conference call and webcast scheduled for August 3, 2023, at 8:00 a.m. ET, to discuss its financial and operational results for the second quarter of 2023. The event aims to provide insights into the company’s performance and is accessible through an online registration process. A replay of the event will be available after the live broadcast for those unable to attend.
Read more →LNTHLantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
Lantheus Holdings, Inc. announced that it will showcase presentations featuring its AI-enabled PYLARIFY technology at the upcoming 2023 SNMMI Annual Meeting. These presentations aim to highlight the real-world applications of standardized PSMA PET reporting, which could significantly enhance prostate cancer patient management. Lantheus expressed confidence in its deep learning-enabled software, emphasizing its commitment to improving patient outcomes. However, the company also noted potential risks associated with market acceptance and operational performance.
Read more →LNTHLantheus to Present at the Jefferies Healthcare Conference
Lantheus Holdings, Inc. will present at the Jefferies Healthcare Conference on June 8, 2023, at 9:00 a.m. ET in New York. The presentation will include insights from CEO Mary Anne Heino and CFO Bob Marshall. Attendees can access the live webcast through the company's website, with a replay available for 30 days. Lantheus aims to enhance patient outcomes with its diagnostic and therapeutic innovations.
Read more →LNTHLantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR
Lantheus Holdings, Inc. announced a payment of $99.7 million to holders of Contingent Value Rights (CVRs) following strong sales of PYLARIFY in 2022. This payment represents the first and final distribution related to the CVRs issued during Lantheus's acquisition of Progenics Pharmaceuticals Inc. in 2020. CVR holders are entitled to a pro rata share based on specific sales thresholds, and this payment satisfies all obligations concerning the CVRs.
Read more →LNTH▲ +15%on this news
Lantheus Reports First Quarter 2023 Financial Results Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year period GAAP net loss of $2.8 million for the fir
Lantheus Holdings, Inc. reported its financial results for the first quarter of 2023, showing a worldwide revenue of $300.8 million, up 44% year-over-year. However, the company experienced a GAAP net loss of $2.8 million, marking a substantial decline from the previous year's profit of $43.0 million. Despite this, Lantheus reported an adjusted fully diluted net income per share of $1.47, an increase from $0.97 a year prior. The company also provided optimistic revenue guidance for both the second quarter and the full year ahead.
Read more →LNTHLantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find,
Read more →LNTHLantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
BEDFORD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023, to discuss its financial and operating results for the first quarter
Read more →LNTHLantheus Announces Two Key Executive Promotions
BEDFORD, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow
Read more →LNTHBurlington Road Bedford, MA 01730 800.362.2668 www.lantheus.com Lantheus Announces Two Key Executive Promotions Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer
Lantheus Holdings, Inc. has announced the promotions of Paul Blanchfield to President and Dan Niedzwiecki to Chief Administrative Officer. Blanchfield, who previously served as Chief Operating Officer and Chief Commercial Officer, brings valuable experience from his background at Takeda Pharmaceutical Co. Niedzwiecki has been with Lantheus since 2013, overseeing legal and corporate matters. These appointments underscore Lantheus's commitment to leadership excellence as the company continues to advance in diagnostics and therapeutics.
Read more →LNTH▲ +20.2%on this news
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the
Lantheus Holdings, Inc. reported its financial results for Q4 and full year 2022, showing a substantial revenue increase of over 103% year-over-year. Despite reporting a net loss in Q4, the company achieved adjusted net income per share significantly higher than the previous year's quarter. The results reflect the success of their core products and an expansion in their oncology pipeline. Looking forward, Lantheus has provided revenue and earnings guidance for Q1 and full year 2023.
Read more →LNTHLantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
BEDFORD, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow
Read more →LNTHLantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
BEDFORD, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023, to discuss its financial and operating results for the fourth q
Read more →LNTHLantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
BEDFORD, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow
Read more →LNTHBurlington Road Bedford, MA 01730 800.362.2668 www.lantheus.com Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer s Disease MK-6240 is an F18-labeled PET imaging agen
Lantheus Holdings, Inc. has acquired Cerveau Technologies, Inc. to enhance their imaging pipeline, specifically targeting Alzheimer's disease with the PET imaging agent MK-6240, which identifies Tau tangles. This acquisition is part of Lantheus's strategy to diversify its radiopharmaceutical offerings and involves transition and development services from Cerveau. Despite the promising potential, challenges exist regarding regulatory approvals and market reception for MK-6240, which is currently being utilized in numerous clinical trials.
Read more →LNTHLantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
BEDFORD, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow d
Read more →LNTHSafe Harbor Statements 2023 Lantheus. All rights reserved. Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigati
Lantheus Holdings produced a Safe Harbor Statement as part of its presentation at the 41st Annual J.P. Morgan Healthcare Conference. The statement outlines forward-looking assertions and the inherent risks associated with them, emphasizing the uncertainties surrounding product approvals, competitive positioning, and market dynamics. It highlights Lantheus's strategic initiatives to maintain leadership in PSMA PET Imaging, while also discussing challenges posed by market competition and external factors like COVID-19. The company aims to leverage its expertise in radiopharmaceuticals to drive future growth.
Read more →LNTHLantheus to Present at the J.P. Morgan 2023 Healthcare Conference
NORTH BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight a
Read more →LNTHLantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma NORTH BILLERICA, MA, December 20, 2022 Lantheus Holdings, Inc. ( Lantheus ) (NASDAQ: LNTH), a company committed to improvi
Read more →LNTHLantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
NORTH BILLERICA, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and
Read more →LNTHLantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027 NORTH BILLERICA, Mass., December 6, 2022 Lantheus Holdings, Inc. (the Company or Lantheus ) (NASDAQ: LNTH), today announced the pricing of $500 million in aggregate principal
Read more →LNTH▼ -8.6%on this newsshared move
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027 NORTH BILLERICA, Mass., December 5, 2022 Lantheus Holdings, Inc. (the Company or Lantheus ) (NASDAQ: LNTH), today announced that it intends to offer, subject to market conditio
Read more →LNTHLantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight a
Read more →LNTHLantheus Announces the Approval of DEFINITY (Perflutren Lipid Microsphere) by China’s NMPA
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and
Read more →LNTHLantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticals Expands Lantheus’ portfolio with license of exclusive worldwide rights, excluding certain territories1, to
Read more →LNTH▼ -12.8%on this news
Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Reports Third Quarter 2022 Financial Results Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 1
Lantheus Reports Third Quarter 2022 Financial Results Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 134.4% from the prior year period GAAP net income of $61.2 million for the third quarter 2022, compared to GAAP net loss of $13.4 mi
Read more →LNTH▼ -12.8%on this news
Lantheus Reports Third Quarter 2022 Financial Results
Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 134.4% from the prior year period GAAP net income of $61.2 million for the third quarter 2022, compared to GAAP net loss of $13.4 million in the prior year period GAAP fully diluted net
Read more →LNTHLantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022, to discuss its financial and operating results for the t
Read more →LNTHLantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
NORTH BILLERICA, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and
Read more →LNTH▼ -6.1%on this news
Lantheus Reports Second Quarter 2022 Financial Results
Worldwide revenue of $223.7 million for the second quarter 2022, representing an increase of 121.4% from the prior year period GAAP net income of $43.1 million for the second quarter 2022, compared to GAAP net loss of $26.7 million in the prior year period GAAP fully diluted ne
Read more →LNTH▼ -6.1%on this news
Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Reports Second Quarter 2022 Financial Results Worldwide revenue of $223.7 million for the second quarter 2022, representing an increase of
Lantheus Reports Second Quarter 2022 Financial Results Worldwide revenue of $223.7 million for the second quarter 2022, representing an increase of 121.4% from the prior year period GAAP net income of $43.1 million for the second quarter 2022, compared to GAAP net loss of $26.7
Read more →LNTHLantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 4, 2022, to discuss its financial and operating results for the sec
Read more →LNTHLantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer
NORTH BILLERICA, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced two key management promotions. Paul Blanchfield has been promoted to Chief Operating Officer (COO) and will continue to report to Mary Anne Heino, Pre
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer Dottie Barr Promoted to Senior Vice President, Manufacturing and Techni
Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations NORTH BILLERICA, MA, June 15, 2022 Lantheus Holdings, Inc. ( the Company ) (NASDAQ: LNTH), today announced two key m
Read more →LNTHLantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer
NORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follo
Read more →LNTHLantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer
NORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follo
Read more →LNTHLantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, F
Read more →LNTHWelcome & Opening Remarks Mark Kinarney Senior Director, Investor Relations Safe Harbor and Non-GAAP Financial Measures Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking sta
Lantheus 2022 Investor Day May 17 | New York City Exhibit 99.1 Welcome & Opening Remarks Mark Kinarney Senior Director, Investor Relations Safe Harbor and Non-GAAP Financial Measures Cautionary Statement Regarding Forward-Looking Statements This document contains forward-loo
Read more →LNTHLantheus Hosts Inaugural Investor Day
NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), will host its Inaugural Investor Day at the Nasdaq MarketSite on Tuesday, May 17, beginning at 9:00 a.m. EDT. Members of Lantheus’ management team will provide updates
Read more →LNTHLantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting
NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, F
Read more →LNTH▲ +7.4%on this newsshared move
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients
NORTH BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, F
Read more →LNTHLantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer
NORTH BILLERICA, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, F
Read more →LNTHLantheus to Present at the UBS Global Healthcare Conference
NORTH BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, F
Read more →LNTH▲ +12.3%on this news
Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results Worldwide revenue of $208.9 million for the first quarter 2022, representing a
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results Worldwide revenue of $208.9 million for the first quarter 2022, representing an increase of 125.8% from the prior year period GAAP net income of $43.0 million for the first quarter 2022, compared to GAAP net i
Read more →LNTH▲ +12.3%on this news
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results
Worldwide revenue of $208.9 million for the first quarter 2022, representing an increase of 125.8% from the prior year period GAAP net income of $43.0 million for the first quarter 2022, compared to GAAP net income of $9.0 million in the prior year period GAAP fully diluted net
Read more →LNTHLantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass., April 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Friday, April 29, 2022, to discuss its financial and operating results for the firs
Read more →LNTHLantheus Appoints Jean-Claude Provost, MD as Interim Chief Medical Officer
NORTH BILLERICA, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find,
Read more →LNTH▲ +8.4%on this news
Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development
NORTH BILLERICA, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find,
Read more →LNTHLantheus Holdings to Present at the Barclays Global Healthcare Conference
NORTH BILLERICA, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Figh
Read more →LNTHLantheus to Host Inaugural Investor Day
NORTH BILLERICA, Mass, March 03, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find,
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member
Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member NORTH BILLERICA, MA., March 1, 2022 - Lantheus Holdings, Inc. ( the Company ) (NASDAQ: LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and
Read more →LNTHLantheus Announces Appointment of Minnie Baylor-Henry as New Board Member
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus’
Read more →LNTH▲ +39.1%on this news· ran to +70% by day 3shared move
Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results Worldwide revenue of $129.6 million and $425.2 million for the
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results Worldwide revenue of $129.6 million and $425.2 million for the fourth quarter and full year 2021, representing an increase of 37.6% and an increase of 25.3% over the prior year period, respective
Read more →LNTH▲ +39.1%on this news· ran to +70% by day 3shared move
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
Worldwide revenue of $129.6 million and $425.2 million for the fourth quarter and full year 2021, representing an increase of 37.6% and an increase of 25.3% over the prior year period, respectively GAAP net loss of $40.2 million and $71.3 million for the fourth quarter and full
Read more →LNTHLantheus Receives U.S. FDA Approval of New Manufacturing Facility
On-site plant will produce DEFINITY® (Perflutren Lipid Microsphere), the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms NORTH BILLERICA, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), a
Read more →LNTHLantheus Announces Presentation Featuring PYLARIFY (Piflufolastat F18) at the 2022 ASCO GU Meeting
NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find,
Read more →LNTHLantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 24, 2022, to discuss its financial and operating results for the
Read more →LNTHLantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer
NORTH BILLERICA, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artific
Read more →LNTHLantheus Appoints Vivian Yao as Chief Human Resources Officer
NORTH BILLERICA, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find,
Read more →LNTHLantheus Announces PYLARIFY AI™ is Now Available
NORTH BILLERICA, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight
Read more →LNTHLantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY (piflufolastat F 18) Injection, Effective January 1, 2022
PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated pr
Read more →LNTHLantheus Holdings Announces Presentations Featuring PYLARIFY (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings
NORTH BILLERICA, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find,
Read more →LNTHLantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight
Read more →LNTH▲ +11.1%on this news· ran to +22% by day 3
Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results
Worldwide revenue of $102.1 million for the third quarter 2021, representing an increase of 15.3% from the prior year period GAAP net loss of $13.4 million for the third quarter 2021, compared to GAAP net loss of $6.4 million in the prior year period GAAP fully diluted net loss
Read more →LNTH▲ +11.1%on this news· ran to +22% by day 3
Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results Worldwide revenue of $102.1 million for the third quarter 2021, representing a
Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results Worldwide revenue of $102.1 million for the third quarter 2021, representing an increase of 15.3% from the prior year period GAAP net loss of $13.4 million for the third quarter 2021, compared to GAAP net loss
Read more →LNTHLantheus Holdings to Present at Upcoming Investor Conferences
NORTH BILLERICA, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight
Read more →LNTHLantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021, to discuss its financial and operating results for the t
Read more →LNTHLantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer
NORTH BILLERICA, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find,
Read more →LNTHLantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment
NORTH BILLERICA, Mass. and HAYWARD, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ pro
Read more →LNTHLantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting
Highlights Piflufolastat F 18’s Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer Identified Regional Lymph Node and/or Distant Metastases in 26.9% of Patients Prior to Definitive Therapy NORTH BILLERICA, Mass., Sept. 10, 2
Read more →LNTH▲ +7.3%on this news
Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results Worldwide revenue of $101.1 million for the second quarter 2021, representing
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results Worldwide revenue of $101.1 million for the second quarter 2021, representing an increase of 53.1% from the prior year period GAAP net loss of $26.7 million for the second quarter 2021, compared to GAAP net l
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Receives U.S. FDA Approval of PYLARIFY (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent fo
Lantheus Receives U.S. FDA Approval of PYLARIFY (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer PYLARIFY will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results Worldwide revenue of $92.5 million for the first quarter 2021, representing an
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results Worldwide revenue of $92.5 million for the first quarter 2021, representing an increase of 2.0% from the prior year period Net income of $9.0 million for the first quarter 2021, compared to net income of $3.3
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel Names Daniel Niedzwiecki as Senior Vice President and
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel Names Daniel Niedzwiecki as Senior Vice President and General Counsel NORTH BILLERICA, MA, April 1, 2021 - Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and f
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results Worldwide revenue of $94.2 million and $339.4 million for the fourth quarter a
Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results Worldwide revenue of $94.2 million and $339.4 million for the fourth quarter and full year 2020, representing an increase of 5.4% and a decline of 2.3% over the prior year period, respectively Net loss of $3.4
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyL TM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Ima
Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent PDUFA action date of May 28, 2021 assigned by U.S. Food and Drug Administration NORTH BILLERICA, MA., December 9, 2020
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Ag
Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement Transaction Extends Relationship with Strategic Partner NORTH BILLERICA, MA., December 3, 2020 - Lantheus Holdings, Inc. (
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY Room Temperature Commercially Available in Early 2021
Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY Room Temperature Commercially Available in Early 2021 NORTH BILLERICA, MA., November 18, 2020 - Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results Worldwide revenue of $88.5 million for the third quarter 2020, representing an
Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results Worldwide revenue of $88.5 million for the third quarter 2020, representing an increase of 3.2% from the prior year period Net loss of $6.4 million for the third quarter 2020, compared to net income of $4.9 mi
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL TM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent
Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent NORTH BILLERICA, MA., September 30, 2020 - Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging,
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portf
Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portfolio of oncology therapeutics and diagnostics to pipeline Worldwide revenue of $66.0 million for the second quarter 2020, represent
Read more →LNTHLantheus Completes Merger with Progenics NORTH BILLERICA, Mass. and NEW YORK--(BUSINESS WIRE)
Lantheus Completes Merger with Progenics NORTH BILLERICA, Mass. and NEW YORK--(BUSINESS WIRE) June 22, 2020 Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ( LMI ), a global leader in the development, manufacture and c
Read more →LNTHLantheus Stockholders Approve Share Issuance For Merger with Progenics
Lantheus Stockholders Approve Share Issuance For Merger with Progenics NORTH BILLERICA, MA - June 16, 2020 Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus or the Company ), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a leader in the development, manufacture and
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results Worldwide revenue of $90.7 million for the first quarter 2020, representing an
Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results NORTH BILLERICA, MA., April 30, 2020 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and comme
Read more →LNTHVelan Capital Agrees to Support Merger of Lantheus and Progenics NORTH BILLERICA, Mass. and New York, NY
Velan Capital Agrees to Support Merger of Lantheus and NORTH BILLERICA, Mass. and New York, NY - April 14, 2020 - Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commerci
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com FOR IMMEDIATE RELEASE Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Fi
Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial BILLERICA, MA - April 9, 2020 - Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus" or the "Company"), parent company of Lantheus Medical Imaging,
Read more →LNTHLantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger
Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger NORTH BILLERICA, MA April 2, 2020 Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a leader in the development,
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results Worldwide revenue of $89.3 million and $347.3 million for the f
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results NORTH BILLERICA, Mass., February 25, 2020 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, m
Read more →LNTHLantheus and Progenics Agree to Amended Transaction Terms Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus C
Lantheus and Progenics Agree to Amended Transaction Terms Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stoc
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial
Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial NORTH BILLERICA, MA, February 3, 2020 Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus or the Company ), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a leader in the development, manufacture and
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings Announces Senior Leadership Appointment Company Appoints Paul Blanchfield as Chief Commercial Officer
Lantheus Holdings Announces Senior Leadership Appointment Company Appoints Paul Blanchfield as Chief Commercial Officer NORTH BILLERICA, MA, January 27, 2020 Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a leader
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings Announces Senior Leadership Appointment Company Appoints Istvan Molnar, M.D. as Chief Medical Officer NORTH BILLERICA, MA, Januar
Lantheus Holdings Announces Senior Leadership Appointment Company Appoints Istvan Molnar, M.D. as Chief Medical Officer NORTH BILLERICA, MA, January 13, 2020 Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a leader
Read more →LNTHLantheus Releases Comprehensive Strategic Plan for Progenics Lantheus Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics Lantheus In-Place Infrastructure and Commercial Cap
Lantheus Releases Comprehensive Strategic Plan for Progenics Lantheus Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics Lantheus In-Place Infrastructure and Commercial Capabilities Will Ensure the Progress of AZEDRA, and the PyL
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Third Quarter 2019 Financial Results Worldwide revenue of $85.8 million for the third quarter 2019, representing a
Lantheus Holdings, Inc. Reports Third Quarter 2019 Financial Results NORTH BILLERICA, Mass., October 31, 2019 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and c
Read more →LNTHLantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus P
Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus Proven Commercial, Manufacturing and Operational Excellence
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Second Quarter 2019 Financial Results Worldwide revenue of $85.7 million for the second quarter 2019, representing
Lantheus Holdings, Inc. Reports Second Quarter 2019 Financial Results NORTH BILLERICA, Mass., July 25, 2019 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and com
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports First Quarter 2019 Financial Results Worldwide revenues of $86.5 million for the first quarter 2019, representing a
Lantheus Holdings, Inc. Reports First Quarter 2019 Financial Results NORTH BILLERICA, Mass., April 30, 2019 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and com
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com FOR IMMEDIATE RELEASE Lantheus Announces Upcoming Retirement of Chief Medical Officer in September 2019 and Promotion of Senior Vice President, Tec
Lantheus Announces Upcoming Retirement of Chief Medical Officer in September 2019 and Promotion of Senior Vice President, Technical Operations to Chief Operations Officer NORTH BILLERICA, Mass., March 25, 2019 Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), parent compa
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results Worldwide revenues of $86.3 million and $343.4 million for four
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results NORTH BILLERICA, Mass., February 19, 2019 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, m
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Third Quarter 2018 Financial Results Worldwide revenues of $88.9 million for the third quarter, an increase of 11.2
Lantheus Holdings, Inc. Reports Third Quarter 2018 Financial Results NORTH BILLERICA, Mass., October 30, 2018 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and c
Read more →LNTHLantheus Holdings Appoints Robert J. Marshall, Jr. as Chief Financial Officer and Treasurer NORTH BILLERICA, Mass. (
Lantheus Holdings Appoints Robert J. Marshall, Jr. as Chief Financial Officer and Treasurer NORTH BILLERICA, Mass. (August 20, 2018) Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ( LMI ), a global leader in the devel
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports 2018 Second Quarter Results DEFINITY worldwide revenues increase 14.9% year over year
Lantheus Holdings, Inc. Reports 2018 Second Quarter Results DEFINITY worldwide revenues increase 14.9% year over year NORTH BILLERICA, Mass., August 1, 2018 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a glo
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports 2018 First Quarter Results DEFINITY worldwide revenues increase 18.4% year over year
Lantheus Holdings, Inc. Reports 2018 First Quarter Results DEFINITY worldwide revenues increase 18.4% year over year NORTH BILLERICA, Mass., May 2, 2018 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings Appoints Gary Pruden, Kenneth Pucel and Dr. James Thrall to its Board of Directors
Lantheus Holdings Appoints Gary Pruden, Kenneth Pucel and Dr. James Thrall to its Board of Directors NORTH BILLERICA, Mass. February 27, 2018 Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ( LMI ), a global leader in
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com FOR RELEASE 4:02 PM ET TUESDAY, AUGUST 1, 2017 Lantheus Holdings, Inc. Reports 2017 Second Quarter Financial Results; Exceeds Second Quarter and Ra
FOR RELEASE 4:02 PM ET TUESDAY, AUGUST 1, 2017 Lantheus Holdings, Inc. Reports 2017 Second Quarter Financial Results; Exceeds Second Quarter and Raises Full-Year 2017 Guidance NORTH BILLERICA, Mass., August 1, 2017 Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), parent
Read more →LNTHInformation Relating to Part II. Item 14. - Other Expenses of Issuance and Distribution The expenses in connection with the offer and sale of shares of common stock of Lantheus Holdings, Inc., registered pursuant to the
Information Relating to Part II. Other Expenses of Issuance and Distribution The expenses in connection with the offer and sale of shares of common stock of Lantheus Holdings, Inc., registered pursuant to the registration statement on Form S-3 (Registration No. 333-215055) fil
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com FOR RELEASE 4:02 PM ET TUESDAY, MAY 2, 2017 Lantheus Holdings, Inc. Reports 2017 First Quarter Financial Results; Exceeds First Quarter and Raises
FOR RELEASE 4:02 PM ET TUESDAY, MAY 2, 2017 Lantheus Holdings, Inc. Reports 2017 First Quarter Financial Results; Exceeds First Quarter and Raises Full-Year 2017 Guidance NORTH BILLERICA, Mass., May 2, 2017 Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), parent compan
Read more →LNTHLantheus and GE Healthcare Announce the Signing of a Definitive License Agreement for Worldwide Development and Commercialization of Flurpiridaz F 18 Companies also announce the extension and expansion of their existing
Lantheus and GE Healthcare Announce the Signing of a Definitive License Agreement for Worldwide Development and Commercialization of Flurpiridaz F 18 Companies also announce the extension and expansion of their existing commercial supply agreement for nuclear products through
Read more →LNTHLantheus Announces Refinancing of its Debt Facility Increases available liquidity; positive impact on cash flow projected to be approximately $5 million per year
Lantheus Announces Refinancing of its Debt Facility Increases available liquidity; positive impact on cash flow projected to be approximately $5 million per year NORTH BILLERICA, Mass., March 30, 2017 Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Im
Read more →LNTHInformation Relating to Part II. Item 14. Other Expenses of Issuance and Distribution The expenses in connection with the offer and sale of shares of common stock of Lantheus Holdings, Inc., registered pursuant to the re
Information Relating to Part II. Item 14. Other Expenses of Issuance and Distribution The expenses in connection with the offer and sale of shares of common stock of Lantheus Holdings, Inc., registered pursuant to the registration statement on Form S-3 (Registration No. 333-21
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports 2016 Fourth Quarter and Full Year Financial Results; Provides 2017 Guidance Company exceeds full year 2016 guidance
Lantheus Holdings, Inc. Reports 2016 Fourth Quarter and Full Year Financial Results; Provides 2017 Guidance Company exceeds full year 2016 guidance, posts revenue of $301.9 million, net income of $26.8 million and Adjusted EBITDA of $78.3 million BILLERICA, Mass., February 21,
Read more →LNTHLantheus Holdings and GE Healthcare Announce the Signing of a Term Sheet for Worldwide Development and Commercialization of Flurpiridaz F 18 NORTH BILLERICA, Mass. & Chalfont St Giles, UK (
Lantheus Holdings and GE Healthcare Announce the Signing of a Term Sheet for Worldwide Development and Commercialization of NORTH BILLERICA, Mass. & Chalfont St Giles, UK (February 21, 2017) Lantheus Medical Imaging, Inc. ( LMI ), a subsidiary of Lantheus Holdings, Inc. ( Lanth
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com IMMEDIATE RELEASE Lantheus Holdings Appoints New Member to its Board of Directors
Lantheus Holdings Appoints New Member to its Board of Directors NORTH BILLERICA, Mass., January 26, 2017 Lantheus Holdings, Inc. ( Lantheus or the Company ) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a global leader in the development, manufacture
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com FOR RELEASE 4:02 PM ET TUESDAY, NOVEMBER 1, 2016 Lantheus Holdings, Inc. Reports 2016 Third Quarter Financial Results Posts Q3 revenue of $73.1 MM,
FOR RELEASE 4:02 PM ET TUESDAY, NOVEMBER 1, 2016 Holdings, Inc. Reports 2016 Third Quarter Financial Results NORTH BILLERICA, Mass., November 1, 2016 Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a global lea
Read more →LNTHMeara Murphy 978-671-8508 LANTHEUS HOLDINGS ANNOUNCES DIVESTITURE OF ITS AUSTRALIAN RADIOPHARMACY SERVICING BUSINESS AND ENTRY INTO LONG-TERM SUPPLY AND DISTRIBUTION AGREEMENT Transaction Simplifies Service and
LANTHEUS HOLDINGS ANNOUNCES DIVESTITURE OF ITS AUSTRALIAN RADIOPHARMACY SERVICING BUSINESS AND ENTRY INTO LONG-TERM SUPPLY AND DISTRIBUTION AGREEMENT Transaction Simplifies Service and Distribution Model in Australia; Expands International Reach of Products NORTH BILLERICA, M
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com FOR RELEASE 4:02
FOR RELEASE 4:02 PM EASTERN THURSDAY, August 4, 2016 Lantheus Holdings, Inc. Reports 2016 Second Quarter Financial Results Lantheus posts second quarter net income of $7.4 million and Adjusted EBITDA of $21.4 million; Second quarter worldwide DEFINITY revenue increased 18% an
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com CONTACTS: Meara Murphy 978-671-8508 Lantheus Holdings, Inc. Reports 2016 First Quarter Financial Results Lantheus posts first quarter net income of
Lantheus Holdings, Inc. Reports 2016 First Quarter Financial Results Lantheus posts first quarter net income of $10.3 million and Adjusted EBITDA of $18.4 First quarter worldwide DEFINITY revenue increased 22% annually NORTH BILLERICA, Mass., May 3, 2016 Lantheus Holdings, In
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com CONTACT: Meara Murphy 978-671-8508 LANTHEUS HOLDINGS ANNOUNCES APPOINTMENT OF JACK CROWLEY AS CHIEF FINANCIAL OFFICER NORTH BILLERICA, Mass., (
LANTHEUS HOLDINGS ANNOUNCES JACK CROWLEY AS CHIEF FINANCIAL OFFICER NORTH BILLERICA, Mass., (March 28, 2016) Lantheus Holdings, Inc. (the Company ) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a global leader in the development, manufacture and com
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com FOR IMMEDIATE RELEASE CONTACT: Meara Murphy 978-671-8508 Lantheus Holdings Announces Retirement of Director Dr. Patrick O Neill; Appoints Two New B
Lantheus Holdings Announces Retirement of Director Dr. Patrick O Neill; Appoints Two New Board Members NORTH BILLERICA, Mass., March 8, 2016 Lantheus Holdings, Inc. ( Lantheus or the Company ) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ( LMI ), a global
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com FOR RELEASE 4:02 PM EASTERN MONDAY, FEBRUARY 22, 2016 CONTACTS: Meara Murphy 978-671-8508 Lantheus Holdings, Inc. Reports 2015 Fourth Quarter and F
FOR RELEASE 4:02 PM EASTERN MONDAY, FEBRUARY 22, 2016 Lantheus Holdings, Inc. Reports 2015 Fourth Quarter and Full Year Financial Results; Provides 2016 Guidance Lantheus posts fourth quarter net income of $3.9 million and Adjusted EBITDA of $18.3 million; Full year adjusted
Read more →LNTHTreble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com CONTACT: Meara Murphy 978-671-8508 LANTHEUS HOLDINGS ANNOUNCES DIVESTITURE OF ITS CANADIAN RADIOPHARMACY OPERATIONS AND COMMENCEMENT OF LONG-TERM S
LANTHEUS HOLDINGS ANNOUNCES DIVESTITURE OF ITS CANADIAN RADIOPHARMACY OPERATIONS AND COMMENCEMENT OF LONG-TERM SUPPLY AGREEMENT Transaction Simplifies Distribution Model in Canada and Improves Operational Efficiencies NORTH BILLERICA, Mass., (January 13, 2016) Lantheus Holdin
Read more →Competitive Position
How LNTH ranks across every disease it competes inCompetitive Position is a premium feature
See how LNTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial